Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug. - Wikidata - awgldk - TriplyDB

Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug.

Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug.

http://www.wikidata.org/entity/Q34650593

about

Toxicology and drug delivery by cucurbit[n]uril type molecular containers Stimuli-Responsive Cucurbit[7]uril-Mediated BSA Nanoassembly for Uptake and Release of Doxorubicin.Acyclic CB[n]-type molecular containers: effect of solubilizing group on their function as solubilizing excipients.Experimental and theoretical investigations of the self-association of oxaliplatin.Complexation of clofazimine by macrocyclic cucurbit[7]uril reduced its cardiotoxicity without affecting the antimycobacterial efficacy.Functionalized cucurbiturils and their applications.Host-guest complexations of local anaesthetics by cucurbit[7]uril in aqueous solution.Recognition-mediated activation of therapeutic gold nanoparticles inside living cells Cucurbit[n]uril based supramolecular assemblies: tunable physico-chemical properties and their prospects.Host-guest interaction of Hoechst 34580 and Cucurbit[7]uril.The ex vivo neurotoxic, myotoxic and cardiotoxic activity of cucurbituril-based macrocyclic drug delivery vehicles.Acyclic cucurbit[n]uril-type molecular containers: influence of aromatic walls on their function as solubilizing excipients for insoluble drugs.Mass spectrometric detection of nanoparticle host-guest interactions in cells.Acyclic cucurbit[n]uril-type molecular containers: influence of glycoluril oligomer length on their function as solubilizing agents.Force and Stress along Simulated Dissociation Pathways of Cucurbituril-Guest Systems Toward Improved Force-Field Accuracy through Sensitivity Analysis of Host-Guest Binding Thermodynamics.Binding enthalpy calculations for a neutral host-guest pair yield widely divergent salt effects across water models.On the Role of Dewetting Transitions in Host-Guest Binding Free Energy Calculations.Acyclic Cucurbit[n]uril-Type Molecular Container Enables Systemic Delivery of Effective Doses of Albendazole for Treatment of SK-OV-3 Xenograft Tumors Variational Implicit-Solvent Modeling of Host-Guest Binding: A Case Study on Cucurbit[7]uril|Cucurbit[7]uril containers for targeted delivery of oxaliplatin to cancer cells Variational Implicit Solvation with Poisson-Boltzmann Theory.Cucurbituril-based supramolecular engineered nanostructured materials.Nanoparticles functionalized with supramolecular host-guest systems for nanomedicine and healthcare.Drug delivery by supramolecular design.Overview of the SAMPL5 host-guest challenge: Are we doing better?Practical applications of supramolecular chemistry.Acyclic cucurbit[n]uril molecular containers enhance the solubility and bioactivity of poorly soluble pharmaceuticals.Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect.Cucurbit[7]uril: an emerging candidate for pharmaceutical excipients.En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2]A pH responsive complexation-based drug delivery system for oxaliplatin Cucurbit[7]uril host-guest complexes of cholines and phosphonium cholines in aqueous solution.Simulations on the possibility of formation of complexes between fluorouracil drug and cucurbit[n]urils: ab initio van der Waals DFT study.Calculating binding free energies of host-guest systems using the AMOEBA polarizable force field.Cucurbituril-based nanoparticles: a new efficient vehicle for targeted intracellular delivery of hydrophobic drugs.Solid-state study of the structure and host-guest chemistry of cucurbituril-ferrocene inclusion complexes.EPR spin Hamiltonian parameters of encapsulated spin-labels: impact of the hydrogen bonding topology.Cucurbit[n]uril binding of platinum anticancer complexes.Supramolecular polymeric biomaterials.

P2860

Q28473864-428423DE-B74A-40B9-B418-875C04BB93C1 Q30395777-61B78E46-4635-4C31-B4E2-582581FCB829 Q30770195-38C40CBC-62B0-4F9D-9B10-906BD88C4641 Q30830211-90D69E41-905A-4A0B-9A75-FA030B981094 Q31116166-997BCA04-B98E-43E8-BC23-064ECAB0C8AF Q33271030-C3A54E95-DECF-4488-9067-773170271530 Q33519960-6EF1C00D-82F9-48F5-B987-9B4182D708AA Q33725235-D1C26C1C-A9B0-4A44-BADB-ABA52CBCD5BA Q33945521-719537E1-9042-43D3-981C-62496FA0D525 Q34019946-251DC9A1-440A-44FF-B71F-FADA72D60917 Q34523282-CF28BEA0-E462-43CB-8119-E6A35D164AC5 Q34631587-EE56BC11-A5E8-4541-BB41-8BE8C800DB8A Q35175719-E755D3A4-2B1A-49B3-B734-BD583C0C7113 Q35196330-DC53BBCB-2DA3-46AC-B10A-CD42DC1B65ED Q36060291-7FB6798D-9E9E-4E1F-996D-09E0822FB1AA Q36331553-E84DCD84-E90F-451A-9632-F8E501B0B96A Q36344868-A694BB3A-E1E1-4666-A8AC-615EBDE86F8C Q36523088-071CF7A1-AE13-4915-A8BF-E434B0A75FCF Q36665183-A27A8F94-402F-4039-A920-A0E738A7FABC Q37162960-EEE0F898-D6AE-46D9-AEF1-DD85A7B099B1 Q37638514-CB2A59AF-2C54-4D4C-85C3-6A29FF7C7955 Q37701462-EF84654E-BA96-4F13-9EEA-AF8AE074B499 Q38269434-BF75A3EF-5A66-40DA-B3D4-266D44E82540 Q38495100-ADFFBF2A-C5CE-4C08-B5EF-B22246F7C1F3 Q38638945-11511203-5B2F-423F-B465-0323EAB0DB35 Q38818618-69E3BB53-E390-4FE7-8417-347BF5DD0543 Q39186762-18B0AD44-EEB3-4D75-AA2B-D6313F47E394 Q39344797-D6F54F26-1315-4A2A-91D7-9647BC4E9D23 Q39345494-F36CB848-B69F-42E3-971C-92C876B70CDF Q39425832-DC091A57-C2E9-46E9-840B-8C89E40CE4BC Q39510416-40E3F9C7-F5D8-4159-83E3-E10EA90AAD1A Q41912667-17AF5438-A939-4733-B36A-6ADC0401B910 Q43213854-BCD284D6-5A33-44E3-8E1B-E5AFD313CBAB Q45098542-9E0196F2-0980-4C83-9032-48F455BA9020 Q45710657-CA1F2999-BD9F-4CFE-A243-6E0BA26A84AE Q46198819-4F7CA458-3B01-42E3-A0CE-CB21FDA28518 Q46471975-4F6270DA-50CF-4631-9A3B-CCDE257DF8B5 Q46502988-BE1381C7-5111-4D6F-94B1-0BBD859BDB5E Q46881282-334697D0-FE41-4224-BF08-E713ACB656C4 Q47325065-B230F633-7DE1-4930-9988-749C3C89630D

P2860

Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug.

http://www.wikidata.org/entity/Q34650593

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@ast

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@en

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@nl

type

label

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@ast

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@en

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@nl

prefLabel

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@ast

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@en

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@nl

P1433

Q34650593-6BE227F7-DE8C-422D-A6DC-A313EF22CEA0

P1476

Q34650593-4C13335F-FFA6-45EE-8878-0ACC07903A61

P2093

Q34650593-19B4F008-AE8D-4436-9FC3-F9D5034467D0

Q34650593-73D2FADD-60A5-45FE-9600-34FCF43CD675

Q34650593-81A72AA5-5E6E-4AF6-B88F-8191BE031A58

Q34650593-B612E278-9B63-4E83-B8DB-EF7E494000F6

Q34650593-DB685CCE-5A13-4A21-A5B2-DEA0C3888CE0

Q34650593-F178DE80-7A2F-44F2-B608-A2FA30AD8D6A

P304

Q34650593-A4780740-73C2-41FE-A0C5-7851866836D4

P31

Q34650593-D3204774-3D26-4ACA-AB68-FB741FEA396B

P356

Q34650593-89C71801-D40C-4396-A7E0-B9EEE425E87F

P433

Q34650593-83ED4C55-12AE-47D9-9F6C-5C996B1BC5E7

P478

Q34650593-23ACB98F-2BE5-4F81-852B-651604039B30

P577

Q34650593-2079B442-0B29-4998-95BE-202209C0A661

P5875

Q34650593-79FC1B19-8EE9-4F59-BA46-F71FE597F65E

P698

Q34650593-E3E58B21-41A9-48E2-A5E8-7B5431FAE9EE

P356

P1433

Organic and Biomolecular Chemistry

P1476

Novel molecular drug carrier: ...... ty and reactivity of the drug.

@en

P2093

Kentaro Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Kimoon Kim

http://www.w3.org/2001/XMLSchema#string

Shigeru Sakamoto

http://www.w3.org/2001/XMLSchema#string

Soo-Young Kim

http://www.w3.org/2001/XMLSchema#string

Young Ho Ko

http://www.w3.org/2001/XMLSchema#string

Young Jin Jeon

http://www.w3.org/2001/XMLSchema#string

P304

2122-2125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/B504487A

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7823650

http://www.w3.org/2001/XMLSchema#string

P698

15917899

http://www.w3.org/2001/XMLSchema#string